BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38304256)

  • 1. High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
    Dhar S; Chakravarti M; Ganguly N; Saha A; Dasgupta S; Bera S; Sarkar A; Roy K; Das J; Bhuniya A; Ghosh S; Sarkar M; Hajra S; Banerjee S; Pal C; Saha B; Mukherjee KK; Baral R; Bose A
    Front Immunol; 2023; 14():1303959. PubMed ID: 38304256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
    Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia (CLL) microenvironment.
    Kowalska W; Bojarska-Junak A
    Folia Histochem Cytobiol; 2020; 58(1):25-36. PubMed ID: 32227331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
    Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
    Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
    Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
    JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
    Tsavaris N; Kosmas C; Zorzos H; Lazaris A; Vadiaka M; Dimitrakopoulos A; Siakantaris MP; Rokana S; Papalambros E; Pangalis GA; Davaris P
    Oncol Rep; 2004 Apr; 11(4):899-903. PubMed ID: 15010892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma.
    Sato Y; Shimizu K; Shinga J; Hidaka M; Kawano F; Kakimi K; Yamasaki S; Asakura M; Fujii SI
    Oncoimmunology; 2015 Mar; 4(3):e995541. PubMed ID: 25949922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
    Kaplan LD; Lee JY; Ambinder RF; Sparano JA; Cesarman E; Chadburn A; Levine AM; Scadden DT
    Blood; 2005 Sep; 106(5):1538-43. PubMed ID: 15914552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma.
    Zhao Q; Huang L; Qin G; Qiao Y; Ren F; Shen C; Wang S; Liu S; Lian J; Wang D; Yu W; Zhang Y
    Cancer Lett; 2021 Oct; 518():35-48. PubMed ID: 34139285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis).
    Yokoyama M; Kusano Y; Inoue N; Nishimura N; Mishima Y; Nukada T; Hatake K; Terui Y
    BMC Cancer; 2021 Apr; 21(1):358. PubMed ID: 33823836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin's Lymphoma or Mantle-Cell Lymphoma.
    Edina BC; Rinaldi I
    Acta Med Indones; 2022 Apr; 54(2):316-323. PubMed ID: 35818660
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Bascuas T; Moreno M; Grille S; Chabalgoity JA
    Front Immunol; 2018; 9():7. PubMed ID: 29410666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
    Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
    Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
    Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
    Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.